

OTPE TO 2004 DE THE

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this day of October, 2004.

Ву	Huch J. Welaney	
	(Signature of person mailing) Sarah J. Delaney	
	(Typed or printed name of person)	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Frank Lombardo, et al.

APPLICATION NO.: 10/081,784 : Examiner: Jan M. Ludlow

FILING DATE: 02/21/2002 : Group Art Unit: 1743

TITLE: TOOL FOR LIPOPHILICITY DETERMINATION:

IN DRUG DISCOVERY BASIC AND NEUTRAL

COMPOUNDS

Hon. Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450

Madam or Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicants herein make available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 that lists the references cited by the applicants, copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTOFB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

The Commissioner is here authorized to charge any additional fees, which may be INFORMATION DISCLOSURE STATEMENT, 9/99, (1/2)

OT 2 2004 Prequired under 37 C.F.R. 1.16

required under 37 C.F.R. 1.16 and 1.17, or credit any overpayment, to Account. No. 161445.

A prompt and favorable response is earnestly solicited.

Date: 10/18/2004

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-1139

Respectfully submitted,

Kathleen A. Ranney Attorney for Applicants Reg. No. 37,702

0 2004 2	ION DISCLOSURE CITATION	ATTY. DOCKET NO. PC11861A	SERIAL NO.	10/081,784	
se several sheets if necessary)		APPLICANT Frank Lombardo, et al.			
Aibi	•	FILING DATE 02/21/2002	GROUP	1743	
	OTHER DOCUMENTS - CON	TINUED (Including Author, Title, Da	ate, Pertinent Pages, Et	c.)	
		evelopment for chiral separation in drug y-mass spectrometry, Journal of Chrom			
	Di, Li et al., Profiling drug-like pro	pperties in discovery research, Chemica	ıl Biology, (2003), 7(3), 40	2-408.	
		profiling method for lipophilicity and inte tography, B: Analytical Technologies in			
		eversed-phase column (Supelcosil LC-A water partition coefficients, Analyst (Ca			
	Lubisch, W. et al., Benzoylalanine-Derived Ketoamides Carrying Vinylbenzyl Amino Residues: Discovery of Potent Watr-Soluble Calpain Inhibitors with Oral Bioavailability, Journal of Medicinal Chemistry, (2003), 46(12), 2404-2412.				
	Katoch-Rouse, R. et al., Synthesis, Structure-Activity Relationship and Evaluation of SR141716 Analogues: Development of Central Cannabinoid Receptor Ligands with Lower Lipophilicity, Journal of Medicinal Chemistry, (2003), 46(4), 642-645.				
	Avdeef, A. et al., Physicochemical profiling in drug research: a brief survey of the state-of-the-art of experimental techniques, Cellular and Molecular Life Sciences (2002), 59(10), 1681-1689.				
	Zhao, Y. et al., High-throughput logP measurement using parallel liquid chromatography/ultraviolet/mass spectrometry and sample-pooling, Rapid Communications in Mass Spectrometry (2002), 16(16), 1548-1555.				
	Atkinson, F. et al., Lipophilicity and other parameters affecting brain penetration, Current Medicinal Chemistry: Cent Nervous System Agents (2002), 2(3), 229-240.				
		Volume of Distribution Values in Huma and Plasma Protein Binding Data, Jour			
	Kerns, E., et al., Multivariate pha (Hilversum, Netherlands) (2002),	rmaceutical profiling for drug discovery, 2(1), 87-98.	Current Topics in Medicin	nal Chemistry,	
AMINER		DATE CONSIDERED			
<u> </u>	reference considered, whether or not citation is in conf				